Compare ULCC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | PRCT |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2021 |
| Metric | ULCC | PRCT |
|---|---|---|
| Price | $6.54 | $19.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $5.21 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 4.0M | 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | $308,054,000.00 |
| Revenue This Year | $23.76 | $31.34 |
| Revenue Next Year | $11.48 | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $3.02 | $17.96 |
| 52 Week High | $8.41 | $62.17 |
| Indicator | ULCC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 35.85 |
| Support Level | $4.58 | N/A |
| Resistance Level | $6.66 | $29.27 |
| Average True Range (ATR) | 0.47 | 1.46 |
| MACD | -0.22 | -0.09 |
| Stochastic Oscillator | 11.94 | 20.67 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.